Meningiomas are the most frequent histotypes of tumors of the central nervous system. Their incidence is approximately 35% of all primary brain tumors. Although they have the status of benign lesions, meningiomas are often associated with a decreased quality of life due to focal neurological deficits that may be related. The optimal treatment is total resection. Histological grading is the most important prognostic factor. Recently, molecular alterations have been identified that are specifically related to particular phenotypes and, probably, are also responsible for grading, site, and prognostic trend. Meningiomas recur in 10–25% of cases. In these cases, and in patients with atypical or anaplastic meningiomas, the methods of approach are relatively insufficient. To date, data on the molecular biology, genetics, and epigenetics of meningiomas are insufficient. To achieve an optimal treatment strategy, it is necessary to identify the mechanisms that regulate tumor formation and progression. Combination therapies affecting multiple molecular targets are currently opening up and have significant promise as adjuvant therapeutic options. We review the most recent literature to identify studies investigating recent therapeutic treatments recently used for meningiomas.
脑膜瘤是中枢神经系统中最常见的肿瘤组织类型，约占所有原发性脑肿瘤的35%。尽管被归类为良性病变，脑膜瘤常因可能相关的局灶性神经功能缺损而导致患者生活质量下降。全切除术是最佳治疗方案，而组织学分级是最重要的预后因素。近年来研究发现，特定分子改变与特定表型密切相关，并可能影响肿瘤分级、发生部位及预后趋势。脑膜瘤复发率为10%-25%，对于复发患者及非典型或间变性脑膜瘤患者，现有治疗手段相对有限。目前关于脑膜瘤分子生物学、遗传学及表观遗传学的研究数据仍不充分。为实现最佳治疗策略，必须明确调控肿瘤形成与进展的分子机制。针对多分子靶点的联合疗法正在兴起，并显示出作为辅助治疗方案的巨大潜力。本文通过综述最新文献，系统考察了当前应用于脑膜瘤治疗的最新疗法研究进展。
Novel Advances in Treatment of Meningiomas: Prognostic and Therapeutic Implications
肿瘤(癌症)患者之家